4,096 results on '"Ponikowski, Piotr"'
Search Results
2. High-intensity care for GDMT titration
3. Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis
4. The role of urine chloride in acute heart failure
5. Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis
6. Author Correction: Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
7. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
8. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
9. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2
10. Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis
11. Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation
12. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial
13. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
14. Association of Reduced Left Atrial Reserve With Exercise Intolerance and Outcome in Hypertension
15. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk
16. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
17. Iron deficiency in heart failure
18. Heart failure clinical assessment
19. Ancillary procedures
20. Inotropes and inodilators
21. Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
22. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
23. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
24. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial
25. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
26. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial
27. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF
28. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
29. Contribution of reduced skeletal muscle perfusion reserve to exercise intolerance in heart failure with preserved ejection fraction
30. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial
31. Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial
32. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
33. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
34. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic
35. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial
36. Global Rounds: Poland
37. Relationship of Vascular Endothelial Growth Factor C, a Lymphangiogenesis Modulator, With Edema Formation, Congestion and Outcomes in Acute Heart Failure
38. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial
39. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
40. Role of Lymphatics in Heart Failure
41. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
42. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
43. Pressure–Volume Profiles in Heart Failure Across Sexes and Phenotypes
44. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
45. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
46. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
47. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
48. Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency
49. Safety, Feasibility of Controllable Decrease of Vena Cava Pressure by Doraya Catheter in Heart Failure
50. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.